+44-1518081136Perspective - Journal of Clinical Research and Pharmacy (2023) Volume 6, Issue 1
Ivermectin′s therapeutic potential as an additional Covid−19 treatment
Ivermectin, a drug that has been used for decades to treat parasitic infections, has recently emerged as a potential treatment for COVID-19. In vitro studies have shown that ivermectin can inhibit the replication of SARS-CoV-2, the virus that causes COVID-19. In addition, observational studies and randomized controlled trials have suggested that ivermectin can reduce the severity and duration of COVID-19 symptoms, as well as the need for hospitalization and oxygen therapy. Although the mechanisms by which ivermectin exerts its antiviral effects are not yet fully understood, it is thought to inhibit viral replication by targeting various host factors that are involved in the viral life cycle. In addition, ivermectin has been shown to have immunomodulatory effects, which could be beneficial in reducing the cytokine storm and inflammation associated with severe COVID-19.
Author(s): Mario Niklas